Sinobioway Medicine(SZ:002581) Zheng Quan Zhi Xing·2025-08-20 22:40Core Viewpoint - ST Unimed (002581) reported significant declines in revenue and net profit for the first half of 2025, indicating severe operational challenges and financial distress [1] Financial Performance Summary - Total revenue for the first half of 2025 was 70.77 million yuan, a decrease of 66.42% year-on-year [1] - Net profit attributable to shareholders was -67.30 million yuan, down 127.26% year-on-year [1] - Gross margin was 70.19%, a decline of 12.97% compared to the previous year [1] - Net margin was -124.57%, a drop of 958.12% year-on-year [1] - Total expenses (selling, administrative, and financial) accounted for 184.83% of revenue, an increase of 116.55% year-on-year [1] Cash Flow and Financial Ratios - Operating cash flow per share was -0.22 yuan, a decrease of 183.51% year-on-year [1] - The company’s return on invested capital (ROIC) over the past decade has been weak, with a median of 0.66% and a worst year in 2023 at -13.03% [2] - The average operating cash flow over the past three years relative to current liabilities was -55.08% [2] Operational Challenges - The significant drop in revenue and profit was attributed to the suspension of production and sales by subsidiaries [1] - The company has experienced five years of losses since its listing, indicating a history of financial instability [2] - The decline in financial expenses was due to reduced loan interest payments, but overall financial health remains concerning [1]